

Kathryn Schnippel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7543365/publications.pdf>

Version: 2024-02-01

47
papers

1,744
citations

430874

18
h-index

276875

41
g-index

48
all docs

48
docs citations

48
times ranked

2221
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonfatal Firearm Injuries by Intent in the United States: 2016-2018 Hospital Discharge Records from the Healthcare Cost and Utilization Project. <i>Western Journal of Emergency Medicine</i> , 2021, 22, 462-470.	1.1	14
2	The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 94.	2.4	20
3	Delay to diagnosis and breast cancer stage in an urban South African breast clinic. <i>South African Medical Journal</i> , 2019, 109, 159.	0.6	14
4	Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 358-362.	1.2	11
5	Unraveling the South African Breast Cancer Story: The Relationship of Patients, Delay to Diagnosis, and Tumor Biology With Stage at Presentation in an Urban Setting. <i>Journal of Surgical Research</i> , 2019, 235, 181-189.	1.6	3
6	Breast abnormalities in adolescents receiving antiretroviral therapy. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 1017.	0.9	1
7	Age Differences by Sex in Antiretroviral-Naïve Participants: Pooled Analysis from Randomized Clinical Trials. <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 371-382.	1.0	5
8	The Effect of Access to Information on Beliefs Surrounding Breast Cancer in South Africa. <i>Journal of Cancer Education</i> , 2018, 33, 806-813.	1.3	5
9	Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 43-54.	2.1	17
10	Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. <i>BMC Health Services Research</i> , 2018, 18, 973.	2.2	26
11	High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. <i>European Respiratory Journal</i> , 2018, 52, 1801528.	6.7	92
12	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	13.7	452
13	Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 918-925.	1.2	10
14	Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 699-706.	10.7	189
15	Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 393-398.	1.2	10
16	Male Breast Cancer Has Limited Effect on Survivor's Perceptions of Their Own Masculinity. <i>American Journal of Men's Health</i> , 2017, 11, 246-252.	1.6	13
17	Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1871-1879.	3.0	41
18	Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/µl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa. <i>PLoS ONE</i> , 2017, 12, e0171675.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals. PLoS ONE, 2017, 12, e0182154.	2.5	5
20	Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1106-1111.	1.2	14
21	Fear of Treatments Surpasses Demographic and Socioeconomic Factors in Affecting Patients With Breast Cancer in Urban South Africa. Journal of Global Oncology, 2017, 3, 125-134.	0.5	10
22	Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLoS ONE, 2017, 12, e0181238.	2.5	7
23	Outcomes of treatment of drug-susceptible tuberculosis at public sector primary healthcare clinics in Johannesburg, South Africa: A retrospective cohort study. South African Medical Journal, 2016, 106, 1002.	0.6	11
24	Missed appointments among rifampicin-resistant tuberculosis (RR-TB) patients at a decentralised RR-TB outpatient clinic in Johannesburg, South Africa. South African Medical Journal, 2016, 106, 912.	0.6	6
25	A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. South African Medical Journal, 2016, 106, 333.	0.6	6
26	Prospective One Year Follow Up of HIV Infected Women Screened for Cervical Cancer Using Visual Inspection with Acetic Acid, Cytology and Human Papillomavirus Testing in Johannesburg South Africa. PLoS ONE, 2016, 11, e0144905.	2.5	9
27	Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1040-1045.	1.2	10
28	Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infectious Diseases, 2016, 16, 593.	2.9	23
29	A Data-Driven Evaluation of the Stop TB Global Partnership Strategy of Targeting Key Populations at Greater Risk for Tuberculosis. PLoS ONE, 2016, 11, e0163083.	2.5	5
30	Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS ONE, 2016, 11, e0164974.	2.5	12
31	Choropleth Mapping of Cervical Cancer Screening in South Africa Using Healthcare Facility-level Data from the National Laboratory Network. AIMS Public Health, 2016, 3, 849-862.	2.6	13
32	Compliance to HIV treatment monitoring guidelines can reduce laboratory costs. Southern African Journal of HIV Medicine, 2016, 17, 449.	0.9	2
33	Cost-effectiveness of using the Cervex-Brush (broom) compared to the elongated spatula for collection of conventional cervical cytology samples within a high-burden HIV setting: a model-based analysis. BMC Health Services Research, 2015, 15, 499.	2.2	8
34	Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. International Journal of Infectious Diseases, 2015, 39, 89-94.	3.3	31
35	Delays, interruptions, and losses from prevention of mother-to-child transmission of HIV services during antenatal care in Johannesburg, South Africa: a cohort analysis. BMC Infectious Diseases, 2015, 15, 46.	2.9	21
36	Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 979-985.	1.2	129

#	ARTICLE	IF	CITATIONS
37	Cost Evaluation of Reproductive and Primary Health Care Mobile Service Delivery for Women in Two Rural Districts in South Africa. PLoS ONE, 2015, 10, e0119236.	2.5	16
38	Estimating Implementation and Operational Costs of an Integrated Tiered CD4 Service including Laboratory and Point of Care Testing in a Remote Health District in South Africa. PLoS ONE, 2014, 9, e115420.	2.5	25
39	Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Tropical Medicine and International Health, 2013, 18, 109-116.	2.3	40
40	Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough. AIDS Research and Treatment, 2013, 2013, 1-7.	0.7	30
41	Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. International Journal of Tuberculosis and Lung Disease, 2013, 17, 368-372.	1.2	32
42	Diagnosing Xpert MTB/RIF negative TB: Impact and cost of alternative algorithms for South Africa. South African Medical Journal, 2013, 103, 101.	0.6	27
43	Impact and cost of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. South African Medical Journal, 2013, 103, 436.	0.6	2
44	Rapid Point-of-Care CD4 Testing at Mobile HIV Testing Sites to Increase Linkage to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e13-e17.	2.1	88
45	How to Estimate the Cost of Point-of-Care CD4 Testing in Program Settings: An Example Using the Alere Pima™ Analyzer in South Africa. PLoS ONE, 2012, 7, e35444.	2.5	48
46	The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE, 2012, 7, e36966.	2.5	126
47	Scaling up Xpert MTB/RIF technology: the costs of laboratory vs. clinic-based roll-out in South Africa. Tropical Medicine and International Health, 2012, 17, 1142-1151.	2.3	54